New Opportunity for COVID Therapeutics by Eric Jia-Sobota
For the past 18 months companies have been confused and frustrated by the shifting USG policies regarding the development of therapeutics as part of the COVID-19 response. BARDA was back and forth as parts of the BAA were suspended, unsuspended, and resuspended. The American rescue Plan legislation was passed about six months ago and although
New Opportunity for COVID Therapeutics by Eric Jia-Sobota Read More »